Timely administration of antibiotics is associated with a reduction in mortality among patients with cirrhosis and upper gastrointestinal bleeding (UGIB), according to a study published in the November issue of Clinical Gastroenterology and Hepatology.
The overall risk of hepatic decompensation in patients treated with the paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) regimen during and up to 12 weeks after completion of treatment was low, Adeel A. Butt, MD, MS, of the VA Pittsburgh Healthcare System, Pittsburgh, PA, told IDWeek 2016 attendees.
Adding rifaximin to lactulose treatment for acute hepatic encephalopathy did not shorten hospital length of stay but it did lower readmission rates at 180 days, study authors reported in a study published in the Journal of Pharmacy Practice.
Complementary and alternative medicine (CAM)-induced drug-induced liver injury (DILI) is as severe in presentation as that seen with prescription medicine (PM)-induced DILI with higher rates of transplantation and lower transplant-free survival in patients who progress to acute liver failure, a new report in The American Journal of Gastroenterology has shown.
Mycophenolate mofetil appears safe and effective for the treatment of autoimmune hepatitis (AIH), according to the results of a study published in Alimentary Pharmacology & Therapeutics.
A case of hepatitis E virus (HEV) infection has been reported in a kidney transplant recipient, according to a research letter published online March 1 in the Annals of Internal Medicine.
In patients with minimal hepatic encephalopathy, nutritional therapy is effective and improves HRQOL, a randomized controlled trial presented during The Liver Meeting® 2015 has reported.
In patients with minimal hepatic encephalopathy, prophylactic lactulose treatment improves cognition, quality of life, and intestinal microbiota, results of a multicenter, randomized, controlled trial presented at The Liver Meeting® 2015 have shown.
Adding everolimus (EVR) to reduced-tacrolimus (TAC) or eliminating TAC is associated with reduced long-term weight gain among patients who undergo liver transplantation, according to a study reported at the The Liver Meeting® 2015.
Sorafenib was associated with a modest survival benefit in patients with advanced hepatocellular carcinoma (HCC), particiularly in patients with decompensation, data presented at The Liver Meeting® 2015 presented.
Entecavir is associated with longer survival times than lamivudine among patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC), according to a study reported at the The Liver Meeting® 2015.
Proton pump inhibitors (PPIs) are safe and effective in reducing the rate of recurrent bleeding among patients with cirrhosis and acute variceal bleeding, according to a single-institution case-control study reported at the The Liver Meeting® 2015.
Response rates among patients with advanced liver cirrhosis who were administered carvedilol to reduce portal pressure were superior to those achieved with propranolol, according to authors of the randomized, open-label, long-term CARPE study. Findings were reported at The Liver Meeting® 2015.
Patients from the advanced cirrhosis cohort of the Phase 3 ALLY-1 study had high rates of sustained virologic response (SVR12) when treated with daclatasvir/sofosbuvir/ribavirin, as well as improved clinical and biochemical indicators of liver disease, investigators reported at The Liver Meeting® 2015.
Cirrhotic patients who develop hepatocellular carcinoma (HCC) despite secondary prevention therapy with nucleos(t)ide analog (NUC) treatment appear to have poor recurrence-free survival (RFS) after surgery than those who do not undergo secondary prevention, reported authors of a new study presented at The Liver Meeting® 2015.
Non-adherence to antiviral regimens may be predicted by the use of pegylated interferon, ribavirin, duration of treatment, and lower baseline and on-treatment patient-reported outcomes (PRO) scores, reported Zobair Younossi, MD, MPH, from Inova Fairfax Hospital, Falls Church, VA, at The Liver Meeting® 2015.
Use of aspirin significantly reduced the risk of three subtypes of cholangiocarcinoma, data presented at The Liver Meeting® 2015 have shown.
Treatment with non-selective beta-blockers in cirrhotic patients with refractory ascites may further deteriorate cardiac function, researchers reported at The Liver Meeting® 2015.
The FDA is warning consumers to stop using Tri-Methyl Xtreme, a dietary supplement marketed to contain anabolic steroids for muscle growth.
Salix announced results from the Phase 3 TARGET 3 trial evaluating the use of repeat treatment with rifaximin 550mg in patients with irritable bowel syndrome with diarrhea (IBS-D).
USPlabs LLC is recalling certain OxyElite Pro dietary supplement products after a letter from the FDA stated that the products have been linked to liver illnesses and that there is reasonable probability that the products are adulterated.
Echosens' FibroScan device, used in the clinical management of patients with liver disease such as chronic viral hepatitis C and B and fatty liver diseases, has received clearance from the FDA.
Liver graft survival, postoperative complications, and the prevalence of primary liver dysfunction in suboptimal grafts are all significantly improved by the infusion of N-acetylcysteine (NAC) during liver procurement.
The proportion of livers not used for transplantation is increasing, with the primary causes being donation after cardiac death (DCD), older donor age, greater body mass index (BMI), and increasing diabetes prevalence.
PharmaIN and LAT Pharma announced that the FDA has granted their request for orphan drug designation for terlipressin for the treatment of ascites due to all etiologies except for cancer.
A new technique involving recellularization of a deceased donor vein graft with autologous stem cells may be a viable option for patients who require a vein graft.